Cancer of unknown primary origin pathophysiology
|
Cancer of unknown primary origin Microchapters |
|
Differentiating Cancer of Unknown Primary Origin from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cancer of unknown primary origin pathophysiology On the Web |
|
American Roentgen Ray Society Images of Cancer of unknown primary origin pathophysiology |
|
Cancer of unknown primary origin pathophysiology in the news |
|
Risk calculators and risk factors for Cancer of unknown primary origin pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Roukoz A. Karam, M.D.[2]
Overview
The exact pathogenesis of cancer of unknown primary origin is not fully understood.
Pathophysiology
Physiology
The normal physiology of [name of process] can be understood as follows:
Pathogenesis
- The exact pathogenesis of cancer of unknown primary origin is not fully understood.
- Cancer of unknown primary, like other cancers, arises from one cell that has managed to escape regulation and produces a tumor at a certain site (the site of origin) and consequently metastasizes to other parts of the body.
- It is thought that the site of origin of CUP remains unknown due to one or more of the following theories:[1]
- Remaining small and undetectable clinically
- Disappearing after metastasizing
- Elimination by body's defense
- It remains unknown whether cancers of unknown primaries are genetically or phenotypically distinct from metastasis with known origins.[1]
Genetics
The factors that keep the primary site of CUP hidden have not yet been identified.
Several studies noted consistency between metastatic cancer of unknown primary and metastases with known primary origins based on chromosomal abnormalities and overexpression of several genes including:
References
- ↑ 1.0 1.1 Varadhachary GR (2007). "Carcinoma of unknown primary origin". Gastrointest Cancer Res. 1 (6): 229–35. PMC 2631214. PMID 19262901.
- ↑ Hainsworth JD, Lennington WJ, Greco FA (2000). "Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site". J Clin Oncol. 18 (3): 632–5. doi:10.1200/JCO.2000.18.3.632. PMID 10653878.
- ↑ Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E; et al. (1998). "Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study". Anticancer Res. 18 (3B): 1907–14. PMID 9677443.